

**Review Article**

# Specific issues in the management of hepatocellular carcinoma in Hepatitis B Virus/Hepatitis C Virus-Human Immunodeficiency Virus co-infected patients

## ABSTRACT

Hepatocellular carcinoma (HCC) has become in recent years a leading cause of morbidity and mortality in patients with HIV who are co-infected with HBV/HCV . The aim of this review is to describe the peculiarities of HCC occurring in this highly demanding scenario, covering all topics from diagnosis to treatment. The epidemiology of co-infection with hepatitis B and C is covered. The following sections deal with suggestions and recommendations about screening, diagnosis and treatment. The key role of liver ultrasound imaging and serum alpha-fetoprotein determination for HCC early diagnosis in patients at high risk for HCC development is underscored. All current treatments of HCC in this special population are described and commented, i.e. surgical resection, percutaneous ethanol injection, radiofrequency ablation, transarterial chemoembolization, targeted therapy, liver transplant. Special consideration has been given to the issues hindering the access of HIV patients with HCC to liver transplantation programmes. We hint to the much awaited availability of highly efficacious anti-HCV Directly Active Antivirals. In fact, the advent of these molecules is likely to produce a deep impact on and a dramatic improvement of the natural history of HIV/HCV co-infections. In summary, HCC incidence in patients with HIV who are co-infected with HBV/HCV is on the rise. Early diagnosis is essential to treat patients with the most efficacious treatment options. Treatment of all three viral infections is the key intervention to prevent occurrence of HCC in this population. Nevertheless, large prospective trials are badly needed to assess the optimal management of patients who have cleared HCV but still risk to develop a liver malignancy.

*Keywords: hepatocellular carcinoma, Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, liver transplant*

## 1. INTRODUCTION

Human immunodeficiency virus (HIV)-infected patients have benefited from the diffusion of combination antiretroviral therapy (cART) showing an increased survival with a better quality of life [1-3]. This has allowed conditions with a long latency to occur at higher rates, such as malignancies, both acquired immunodeficiency syndrome defining malignancies (ADMs) and non-ADMs [4-6]. In particular, during the last 10-15 years, where cART was easily accessible, end-stage liver disease (ESLD) emerged as a leading cause of morbidity and mortality among HIV-infected subjects co-infected with

Hepatitis C Virus (HCV) and/or hepatitis B virus (HBV) [4, 7]. An increased incidence of hepatocellular carcinoma (HCC), a clinical complication which takes places several years after the infection with HBV or HCV, has been observed as well [7-10].

It has never been proved that HIV is an independent risk factor for the development of HCC, although chronic hepatitis progression toward cirrhosis has been shown to be progress more rapidly by coinfection with HIV [8-11].

This review reports the updated knowledge on: epidemiology of HBV/HCV-HIV co-infections; epidemiology of HCC in this population; diagnosis, pathogenesis, treatment and prevention of HCC in this specific population of co-infected individuals.

## 2. EPIDEMIOLOGY

Hepatitis B virus and HCV infections present different epidemiological and geographical peculiarities because of their way of acquisition. In fact HCV acquisition is usually related with use of injectable illicit drugs in all Europe, USA and Australia, while in developing countries it is due to a mix (i.v. drug use and iatrogenic transmission). The same modes of transmission are shared by HBV, but sexual contact and vertical transmission remain the main route of infection in endemic areas where vaccination has not yet been introduced. Since HIV shares modes of transmission with both HCV and HBV, even geographical and demographic distributions are shared with both hepatic viruses.

Relative proportions of co-infection with HCV and/or HBV show broad variations among HIV-infected populations and sub-groups in the world depending on the prevalence of different high-risk behaviours in the sub-groups and populations evaluated. In Europe and in the USA, approximately 15–30% of patients infected with HIV are also infected with HCV [12, 13], and, among these patients, the number of deaths due to ESLD is higher than that from acquired immunodeficiency syndrome (AIDS) defining conditions [13, 14].

The highest rates of HCV-HIV co-infection are found among intravenous drug users (IDUs) and prisoners (up to 75–90%) [15-17]. Differently, prevalence of HBV among HIV-infected patients is reported to vary between 5 and 10% in Europe and the USA, while it reaches 15% in countries and settings where HBV is endemic [17-20].

Nevertheless, recorded prevalences are likely to be not precise for several reasons. Testing for HCV antibodies detects 20-25% of subjects in excess who have spontaneously cleared the virus and present undetectable HCV RNA. Few studies of prevalence reported testing also for HCV-RNA, thus we can rely only on those searching uniquely for HCV antibodies. There is general agreement that detection of hepatitis B surface antigen (HBsAg) identifies those with HBV infection. Moreover, a small but significant amount of HBsAg negative patients are presenting detectable HBV DNA and positive anti HBe antibodies. This condition is defined as occult HBV infection and it occurs frequently in HIV patients with HCC and no evidence of coinfection with HCV [21-23]. Its clinical relevance is due to the capability of occult hepatitis B to preserve its oncogenic potential even in presence of minimal viral replication. Actually, a recent study evidenced circulating HBV DNA in most (63.5%) patients with HBsAg-negative HCC [24]. Similarly, another study reported that occult HBV infection was present in the vast majority (up to 70%) of patients with HBsAg-negative HCC [25].

Hence, prevalence studies employing RNA and DNA testing would be more accurate in estimating the actual burden of hepatic viral co-infections among HIV-infected subjects [9].

As to co-infections and HCC, a large retrospective US cohort study (14 018 male patients followed for 8 years up to 2004) reported a much higher risk of HCC among those HIV infected, almost exclusively associated to HCV (and to a lesser extent HBV) infection [26]. Incidence of HCC in HIV-HCV co-infected patients belonging to another large retrospective cohort (1 678 subjects) – including both pre-cART and cART eras – was strikingly higher than in the HCV mono-infected population. The difference between the two populations was really striking during the cART era: only 5 HCC cases during

the years before the introduction of cART versus 22 thereafter [11]. Another report on 2383 HIV-infected patients found a higher than expected incidence of HCC in HCV co-infected subjects compared with the average population [27]. Similar results have been reported by small European retrospective studies

The incidence of HCC among HIV infected subjects showed a constant increase over time, in parallel with introduction of better antiretroviral regimens, up to a 2009 estimate of 30 per 100 000 individuals in the US AIDS population [9, 10]. Recently, a Spanish study reported the incidence of HCC in a prospective cohort of 371 HIV infected patients enrolled between 2004 and 2005, the majority receiving ART, with liver cirrhosis from different causes. Among them the incidence rate of HCC was 6.72 per 1000 person-years [95% confidence interval (CI): 2.6 to 10.9]. There was a trend toward a higher cumulative probability of developing HCC at 6 years of follow up (considering death and liver transplant as competing risks) in patients with decompensated versus compensated cirrhosis at baseline (6% vs. 2%,  $P < 0.06$ ) [28]. Conversely, HCC incidence in the general population is low, e.g. in 2008 it was of 16 cases per 100 000 inhabitants [29]. It ranges from 1.6 per 100 000 inhabitants for North European women up to 35.5 per 100 000 inhabitants for Eastern Asian men [30].

It has to be underscored that studies from the years before cART introduction, or in countries where cART is not universally accessible, have generally reported rates of HCC lower or equal to those observed in the general population [31,32]. The main reason is probably that patients would die of AIDS related conditions long before the prospective development of cirrhosis and subsequently of HCC.

In fact, as recently reported in a studied population where cirrhosis had time to develop, no difference in HCC incidence among cirrhotic HIV-HCV co-infected patients was observed in the pre- and HAART eras [33].

### 3. DIAGNOSIS

Early diagnosis of HCC is crucial for a better management of the disease in co-infected patients. Thus, regular screening of patients with hepatitis and HIV co-infection is needed to reach this objective.

Current European AIDS Clinical Society guidelines give specific recommendations to perform screening of cirrhotic HBV and/or HCV-HIV co-infected individuals [34]. Such recommendations are similar to those released for HCV or HBV mono-infected patients with established cirrhosis, suggesting screening with ultrasonography and alpha-fetoprotein (AFP) level determinations every 6 months [35]. With a slight different approach, US screening guidelines for HIV and HCV coinfecting subjects recommend to employ ultrasonography as the first step in HCC screening [36]. In addition, it is suggested that, only in settings where ultrasonography is not available, AFP determination can be used alone. Nevertheless, screening should be carried out every 6-12 months and should address all those at an increased risk for HCC [37].

To summarize, once the patient is diagnosed with cirrhosis, screening for HCC every 6 months with ultrasonography, coupled or not with AFP, is recommended [30,34-36,38].

Even sustained virological response (SVR) after anti HCV treatment cannot completely arrest the development of HCC in the mid term and long term. It is known that in cirrhotic patients in spite of the absence of the virus after successful eradication with anti-HCV treatment, an increased risk of HCC development persists [39]. Actually, presence or absence of cirrhosis in HIV co-infected patients obtaining SVR after anti HCV treatment is crucial in determining the subsequent risk of HCC occurrence.

Recently, findings from a Spanish study reinforce the need to continue surveillance for HCC with ultrasound examinations in patients with cirrhosis who respond to anti HCV therapy [40]. Indeed, HCC can become manifest even during treatment course, as it has been reported [41]. In particular, the majority of cases in the Spanish series appeared after 1.5 years

since the end of anti HCV therapy and the elapsed time for some cases was even longer than 5 years, as it has been also shown in HCV mono-infected patients [42]. Their findings reinforce the current recommendation of clinical guidelines to maintain HCC surveillance indefinitely in patients with cirrhosis, even for those with SVR who cleared HCV with therapy [36].

Liver nodules need to be detected by ultrasonography during the recommended biannual (i.e. every 6 months) follow up visits. Then, second level imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) should be accessible to characterize such nodules at the earliest possible stages [35]. When nodule nature is not determinable by such imaging techniques, biopsies should be performed with the shortest possible delay. The early characterization of nodules would help in timely addressing the patient to the most appropriate treatment, thus preventing further tumour growth that could make the patient ineligible to curative procedures. Nevertheless, no algorithm has been drawn so far for the HIV-infected population in absence of studies in this specific population [43].

#### 4. RISK FACTORS AND PATHOGENESIS

HCV infection in HIV infected patients frequently causes chronic liver disease potentially leading to cirrhosis and HCC. In the presence of cirrhosis the annual risks of HCC, liver disease progression and death in HCV infected patients are approximatively 1-7%, 5% and 2%, respectively [44]. The principal oncogenic effect of HCV is mediated indirectly through activation of immune-mediated inflammation and its downstream effects on cell proliferation and apoptosis.

HIV-HCV co-infected patients have been shown to develop liver cirrhosis more quickly than HCV mono-infected individuals; in addition, HCC behaviour is more aggressive in these patients [45-49]. Presence of cirrhosis is the essential element for HCC development, in HCV infected subjects; it is observed in 1%-4% of patients per year after cirrhosis occurrence.

The ongoing processes of inflammation and repair in the cirrhotic liver are a significant pathogenic factor for HBV and HCV infections. Specifically for HBV, the degree of viral replication is an additional key factor for HCC development. In fact, patients with active chronic hepatitis B present a 90 fold greater risk of developing HCC than HBV negative (cross matched for age). On the other hand, inactive carriers with low levels of viremia are exposed only to a 9 fold increase. Additionally, the risk of HCC is reported to directly correlate with HBV-DNA levels [50]. The random integration of viral DNA into the host chromosomes (an incidental process not necessary for viral replication) leads to secondary chromosomal rearrangement and genomic instability with oncogenic potential [51].

The quantitative decline of T-cells observed in the immunodeficiency associated with HIV infection is probably the factor behind the impaired viral immune response responsible for acceleration of the course of HCV infection [52].

Specifically, in HIV/HBV co-infected patients, an immune dysregulation related with CD4+ decrease may be observed. This seems to be the mechanism that in HIV infected subjects sustains the specificity of chronic hepatitis B in such population, i.e. higher rates of chronic evolution of acute hepatitis B, higher levels of HBV replication, a lower rate of spontaneous hepatitis B e antigen (HBeAg) and HBsAg loss or seroconversion to anti-HBe and anti-HBs. Cases of seroreversion (i.e. loss of HBsAb and reappearance of HBsAg) have also been reported [14].

Moreover, in the context of co-infection of HIV with either HBV or HCV, additional severe liver injuries may occur in consequence of cART efficacy in rapidly restoring immune function and therefore giving place to the so-called 'immune reconstitution syndrome'. Conversely, ART-related immune restoration can lead to improved cellular immune response to viral hepatitis antigens, thus slowing the progression of chronic liver disease [53].

In addition a weaker **anti-tumor** answer (HCC-driven) has been described in HIV infected patients, mainly due to the chronic low T cell counts. Such reduced immune response to HCC may justify the fast growth and the extension in diffusion of the disease observed in co-infected subjects [54].

## 5. TREATMENT

Notwithstanding a variety of treatment options for HCC (see Table 1), unfortunately, access to treatment for those infected with HIV is different from those not infected. This is particularly true for liver transplantation.

In the HIV negative population, presence of solitary HCC nodule (up to 5 cm) is an indication to surgical resection, associated with a 5-year survival of 50%-70% [30,55,56]. Eligibility for surgery is assessed employing the Milan or the University of California, San Francisco (UCSF) criteria [30,57,58]. When patients present with local disease that cannot be eligible for surgery, they can be offered ethanol injection. Such treatment option is reported to have a ~50% 5-year survival rates [59].

Radiofrequency ablation (RFA) is considered a safe and effective therapy for patients with HCC who cannot undergo resection, or as a bridge to liver transplant; the goal of therapy is to destroy the nodule and 0.5 cm of tissues surrounding it [60,61]. RFA is generally performed percutaneously under US or CT guidance [62]. It is indicated if there is a single nodule  $\leq 5$  cm or up to three nodules  $\leq 3$  cm each [30,63]. Some absolute **contraindications** for RFA include lesions larger than 5 cm, lesions adjacent to vital organs, particularly when adhesions are suspected, or to main biliary ducts; and presence of **bilio-enteric** anastomosis [64]. The therapeutic efficacy could be monitored with a combination of imaging investigations (contrast enhances-US or CT scan) and serum assays [60].

A recent systemic evaluation showed superiority of RFA over percutaneous ethanol injection for the treatment of small HCC [65]. Therefore, it is probable that ethanol injection should be reserved for those ineligible for RFA or where RFA is not available. When diagnosed with a more advanced disease, patients are amenable to palliative transarterial chemoembolization (TACE). Nevertheless, so far, no chemotherapy or targeted therapy showing a survival benefit has been identified for these patients.

HIV infected subjects with non AIDS defining cancers, such as head-neck, lung cancers, etc., generally present at diagnosis at a more advanced stage, thus generally receiving curative treatments less frequently than those HIV negative [66]. Specifically for HCC, an Italian study reported 15 HIV-infected patients with disease within the Milan criteria for liver transplantation eligibility [46]. Nevertheless, none was treated with liver transplantation and only two received surgical resection. In addition, this cohort reported a poor outcome for HIV-infected subjects compared to HIV negative subjects (28% 1 year survival for those HIV-infected vs. 57%). Other reports showed poor access to curative treatment for HIV/HCV co-infected patients [46,67]; while others evidenced better access to proven effective therapy, as TACE for those with HIV infection [47].

TACE and RFA have been employed more frequently for HIV infected subjects, while surgical resection has been carried out more often for those HIV uninfected. A single recent study could report equal access to treatment for HCC for HIV positive and HIV negative patients [68]. Nevertheless, even in this latter study, differences still existed in actual delivery of recommended curative treatment with about 30% of HIV-infected subjects not receiving it. In addition, other authors reported that the reason behind lack of improvement in curative management for HCC for those with HIV infection was probably late initiation of interventions [69].

Nevertheless, no large prospective cohort has clearly demonstrated the true reasons behind poor access to effective and curative treatment for HIV-infected patients. They probably include, among others, difficulties in management of

decompensated cirrhosis, late referral, advanced stage of HCC at diagnosis, deterioration of general health , poor compliance or greater aggressiveness of the tumour.

### **5.1.Liver transplant.**

The current criteria regarding liver status for eligibility to liver transplantation (OLT) for HIV infected patients do not present differences from those agreed upon for those without HIV infection. On the other side, specific HIV related factors (*i.e.*, post-OLT HAART tolerance and CD4 T cell absolute number) have been reported as predictors of mortality in OLT [70]. A stable (for more than six months) absolute CD4+ cell count > 200/mm<sup>3</sup> and an undetectable HIV viral load are required if the patient is receiving HAART and has a previous history of opportunistic infections (*i.e.*, adequately treated tuberculosis, invasive candidiasis, toxoplasma encephalitis, pneumocystosis, etc). Exceptions are represented by patients who have lower absolute CD4+ cell count (*i.e.*, between 100 and 200/mm<sup>3</sup>, potentially related to hypersplenism), but have no history of opportunistic infections, or patients who cannot receive antiretrovirals due to severe liver impairment. In the latter case, previous documentation of therapeutic efficacy and/or genotypic or phenotypic tests documenting the availability of a potentially effective regimen (able to suppress HIV replication to undetectable HIV RNA) for post transplant administration is required [71].

HIV infected patients suffering a first episode of cirrhotic decompensation should be evaluated for liver transplantation, especially if they are under ART with virological response. In the past HIV infection was considered as an absolute contraindication to liver transplantation, but this assumption is gradually changing. In fact, similar survival rates have been reported in HIV positive recipients, when compared to HIV negative MELD-score matched subjects [33,70-78]. Recently, additional specific data on liver transplants in HIV infected recipients with HCC have been published. Such reports with increasing, although still relatively small, numbers showed results comparable to the HIV negative HCC population [79]. Nevertheless, a higher proportion of HIV infected patients appears to die while on the waiting list with late referral being at least partially responsible for increased mortality [80].

A group proposed monitoring of AFP levels during the waiting list phase of HIV infected patients to identify those with higher risk of serious complications after liver transplantation [43]. In fact, a clear correlation between AFP levels (especially when rapid growth is observed) and a poor clinical outcome has been described [81]. However, HCC recurrence has been observed to occur equally among HIV infected transplanted patients and in those HIV negative. In addition, no impact of immunosuppressive treatment has been described on HIV progression, as formerly expected [82].

Liver transplant in HIV infected patients presents specific post transplant challenges. These latter include in particular faster and more aggressive re-infection with HCV, more issues in drug-drug interactions, more common lamivudine resistance in HBV infection (obviously among those HBV co-infected), and a relatively more frequent occurrence of toxicity of some immunosuppressant, such as tacrolimus [70,83].

In summary, HIV infected patients with HCC should be able fully access the complete evaluation steps leading to liver transplantation, and early detection of HCC is key for better management and outcome.

Screening strategy in case of HBV infection is more complex since it must take into account not only liver histology but also the risk factors for developing HCC in the absence of cirrhosis. Actually, some authors have identified for HIV uninfected patients with hepatitis B potential risk scores for HCC that include: age, gender, the length of untreated hepatitis period, a family history of HCC and cirrhosis [35]. These proposed HCC risk scores could probably be employed also for those co-infected with HBV and HIV [43].



## 5.2. Targeted therapy.

The recent introduction of specific treatments for HCC such as sorafenib has offered a new option to improve advanced HCC management [84]. Recent studies among HIV-infected patients with HCC have reported a sorafenib efficacy and safety profile comparable with that observed in HIV uninfected patients [85–87]. Nevertheless, possible drug interactions between antiretroviral drugs and sorafenib at cytochrome P450 level with risk of excessive and more toxic blood levels of the antimitotic agent have been reported [87,88].

More recently, a report about 27 consecutive HIV-infected patients with HCC treated with sorafenib showed an overall survival (12.8 months [1.1–23.5]) comparable to the results obtained by other groups [84, 89]. Nevertheless, as in non HIV infected patients, the main limitation to such treatment remains the presence of cirrhosis associated with liver failure and/or portal hypertension.

## 6. PREVENTION OF HCC

The first step in trying to prevent HCC in HIV infected subjects is treatment of the hepatic co-infections. Actually, main international guidelines for the management of HIV infection already consider – for those subjects co-infected with HBV – mandatory ART including drugs also active against HBV as tenofovir, lamivudine and emtricitabine [50,90-92].

Treatment of chronic hepatitis in HCV/HIV co-infected patients has proven effective and it is recommended by several international guidelines [34, 93-100]. For many years anti HCV treatment has been based on pegylated interferon (IFN) + ribavirin with inconsistent and still unsatisfactory results [98]. New treatment opportunities are opening now with the availability of directly acting agents (DAAs) and some encouraging experiences already exist [95, 99-101].

Sustained virological response rates (SVR) of 27%-40% have been achieved with IFN and ribavirin therapy in HIV co-infected patients [48]. Not only is the risk of HCC reduced with HCV eradication but the resulting enhanced liver function increases tolerance to antiretroviral agents. Treatment of the HIV/HCV patient presents several challenges<sup>[8]</sup>, but it is surely feasible [95, 98-100].

Several studies have shown that the incidence of HCC is lower in HCV infected patients who achieved SVR with IFN based treatment [6, 100-109].

A relatively small advantage in prevention of HCC by IFN treatment, even without obtaining an SVR, has been reported by several authors [110-117]. HCC risk is mainly related to fibrosis and, since antiviral therapy improves fibrosis, it should reduce the risk of developing HCC as well. On the other hand some authors suggest that the benefits of anti HCV therapy could be due to the antifibrotic and antiproliferative properties of IFN, independently of antiviral effects [118]. Actually, if IFN is successful in achieving a persistently and undetectable HCV-RNA, necrotic inflammation should consistently improve. At the same time, carcinogenesis is believed to be suppressed even in biochemical responders who do not achieve viral clearance [119].

As previously mentioned, several studies conducted in patients with cirrhosis have confirmed that incidence of HCC significantly decreases in patients who achieved SVR, but, since cirrhosis is not eliminated, the risk of HCC is not entirely removed [102, 107-109, 120].

Registration trials of anti HCV treatments have usually been restrictive in patient enrolment, not taking into account patients with advanced liver disease or HCC. Thus, treatment of chronic hepatitis C (CHC) in HCC patients has remained an area of limited knowledge as to efficacy and cost/effectiveness. In any case, safety and efficacy of peg-interferon treatment of CHC in patients previously treated for HCC has been proved [40].

Some reports about the usefulness of interferon and ribavirin in the prevention (primary and of recurrence) of HCC in non HIV infected patients have been published [121, 122]. More recently, Italian anti HCV treatment guidelines considered

chronic hepatitis C treatment with peg-interferon + ribavirin as secondary prophylaxis against recurrence of HCC [123] and some experiences to this effect have been published [41]. Prevention of HCC is not exclusively based on treatment of hepatitis B and/or C. Among these patients comorbidities may be present and need to be addressed. They include ART-related toxicity, diabetes, alcohol use, steatosis, and other metabolic disorders [43, 124].

## 7. CONCLUSIONS

Large international cohort studies show that HCC incidence in persons living with HIV keeps rising in regions of the world where ART is currently available. The increasing availability of ART in developing countries can be expected to have similar consequences. Nevertheless, timing of such increase is difficult to predict. Lack of detailed epidemiological data on HBV or HCV co-infection makes it challenging to easily identify and quantify the at-risk population. Recent studies on management of HIV/HBV co-infection confirm that monitoring of HBV viral load (HBV-DNA) is often inadequate in co-infected patients despite regular viro-immunological assessment of HIV infection [125 and personal observation]. Current HCC screening strategies developed for HBV or HCV mono-infected patients are employed among those co-infected with HIV. However, they have never been validated in this specific population. After diagnosis of HCC, patients are referred and have access to effective treatments less frequently and usually at a more advanced stage of the disease. Guidelines on management of HBV/HCV-HIV co-infected patients have been developed, but new scenarios keep arising, highlighting advantages (e.g. anti-viral cross-efficacy, etc) and disadvantages (e.g. cross-resistance, drug-drug interactions, etc). In the near future the availability of several highly efficacious DAAs will dramatically change the natural history of HIV/HCV co-infection with its potential to eradicate HCV infection in virtually all patients. Large prospective trials are still needed to explore in depth the risk factors for developing HCC for those who eradicated HCV and to identify the optimal screening algorithm for an early diagnosis of HCC in the population of co-infected patients.

## REFERENCES

1. Hogg RS, Ealt KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. *JAMA*. 1998; 279:450–4 [PMID: 9466638]
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*. 1998; 338:853–60 [PMID: 9516219]
3. Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, et al. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 <50/mm<sup>3</sup>). *HIV Clin Trials*. 2000; 1:9–16 [PMID: 11590493]
4. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, De Wit S, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? *AIDS*. 2005; 19:2117-25 [PMID: 16284461]
5. Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. *Clin Infect Dis*. 2010; 50:1316-21 [PMID: 20297953; doi: 10.1086/651688]



6. Limketkai BN, Mehta SH, Sutcliffe CG, YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfecting with HIV/HCV. *JAMA*. 2012; 308:370-78 [PMID: 22820790; doi: 10.1001/jama.2012.7844]
7. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). *J Viral Hepat*. 2007; 14:183-8 [PMID: 17305884]
8. Macdonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. *World J Gastroenterology*. 2008; 14:1657-63 [PMID: 18350596]
9. Sahasrabudde VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. *Cancer*. 2012; 118:6226–33 [PMID: 22736272; doi: 10.1002/cncr.27694]
10. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. *Hepatology*. 2013; 57:249–57 [PMID: 22532055; doi: 10.1002/hep.25800]
11. Giordano TP, Kramer JR, Soucek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. *Arch Intern Med*. 2004; 164:2349-54 [PMID: 15557414]
12. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *Clin Infect Dis*. 2002; 34:831–7 [PMID: 11833007]
13. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. *Eur Rev Med Pharmacol Sci*. 2012; 16:1473–83 [PMID: 23111959]
14. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. *Curr Opin HIV AIDS*. 2011; 6:478–82 [PMID: 22001892; doi: 10.1097/COH.0b013e32834bd365]
15. Buffet-Janvresse C, Peigue-Lafeuille H, Benichou J, Vabret A, Branger M, Trimoulet P, et al. HIV and HCV co-infection: situation at six French university hospitals in the year 2000. *J Med Virol*. 2003; 69:7–17 [PMID: 12436472]
16. Pontali E, Ferrari F. Prevalence of Hepatitis B virus and/or Hepatitis C virus co-infections in prisoners infected with the Human Immunodeficiency Virus. *Int J Prison Health*. 2008; 4:77-82 [PMID: 18464061; doi: 10.1080/17449200802038207]
17. Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. *Euro Surveill*. 2008; 13 [PMID: 18761958]
18. Elefsiniotis S, Paparizos V, Botsi C, Pantazis KD, Katsambas A. Serological profile and virological evaluation of hepatitis B and hepatitis C virus infection among HIV infected patients in Greece. *Cent Eur J Public Health*. 2006; 14:22-4 [PMID: 16705877]
19. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and metaanalysis. *Int J Infect Dis*. 2010; 14:1024–31 [PMID: 20870439; doi: 10.1016/j.ijid.2010.06.013]
20. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. *Lancet*. 2012; 380:1840–50 [PMID: 23079588; doi: 10.1016/S0140-6736(12)60919-2]

21. Jardim RN, Gonçalves NS, Pereira JS, Fais VC, Gonçalves Junior FL. Occult hepatitis B virus infection in immunocompromised patients. *Braz J Infect Dis*. 2008; 12:300-5 [PMID: 19030729]
22. Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. *World J Gastroenterol*. 2011; 12:1529-30. [PMID: 21472115; doi: 10.3748/wjg.v17.i12. 1529]
23. Gutiérrez-García ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. *World J Gastroenterol*. 2011; 12:1538-42. [PMID: 21472117; doi: 10.3748/wjg.v17.i12. 1538]
24. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. *Gastroenterology*. 2004; 126:102-10 [PMID: 14699492 ]
25. Shiota G, Oyama K, Udagawa A, Tanaka K, Nomi T, Kitamura A, et al. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. *J Med Virol*. 2000; 62:151-8 [PMID: 11002243]
26. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. *J Clin Oncol*. 2006; 24:5005-9 [PMID: 17075119]
27. Murillas J, Del Rio M, Riera M, Vaquer P, Salas A, Leyes M, et al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. *Eur J Intern Med*. 2005; 16:113-15 [PMID: 15833677]
28. Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J, et al. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. *J Acquir Immune Defic Syndr*. 2014; 65:82-86 [PMID: 24419065; doi: 10.1097/QAI.0b013e3182a685dc]
29. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010; 127:2893–917. [PMID: 21351269; doi: 10.1002/ijc.25516]
30. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet*. 2012; 379:1245–55. [PMID: 22353262; doi:10.1016/S0140-6736(11)61347-0]
31. Beral V, Newton R. Overview of the epidemiology of immunodeficiency-associated cancers. *J Natl Cancer Inst Monogr*. 1998; 23:1-6 [PMID: 9709294]
32. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. *Hematol Oncol Clin North Am*. 2003; 17:673-96 [PMID: 12852650]
33. Di Benedetto F, Tarantino G, Ercolani G, Baccarani U, Montalti R, De Ruvo N, et al. Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. *Oncologist* 2013; 18:592-9 [PMID: 23666950; doi: 10.1634/theoncologist.2012-0255]
34. EACS Guidelines 2013. Version 7.02; available on: [http://www.eacsociety.org/Portals/0/140601\\_EACS%20EN7.02.pdf](http://www.eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf) last access March 15<sup>th</sup> 2015
35. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL–EORTC. Clinical Practice Guidelines: Management of hepatocellular carcinoma *J of Hepatology*. 2012; 56:908–43 [PMID: 22424438; doi: 10.1016/j.jhep.2011.12.001]
36. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011; 53:1020–2 [PMID: 21374666; doi: 10.1002/hep.24199]
37. Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfectd with HIV. *Transplantation*. 2001; 72:1684-8 [PMID: 11726833]

38. Jelic S, Sotiropoulos GC, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 Suppl 5:v59–64 [PMID: 20555104; doi: 10.1093/annonc/mdq166]
39. Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, et al. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. *J Viral Hepat*. 2000; 7:414-9 [PMID: 20555104]
40. Merchante N, Merino E, Rodríguez-Arrondo F, Tural C, Muñoz J, Delgado-Fernández M, et al. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. *AIDS*. 2014; 28:41-7 [PMID: 24056067; doi: 10.1097/QAD.0000000000000005]
41. Cenderello G, Pontali E, Cassola G, Torresin A. Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports. *Infection*. 2013; 41:199-202 [PMID: 23065464; doi: 10.1007/s15010-012-0353-3]
42. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA*. 2012; 308:2584–93 [PMID: 23268517; doi: 10.1001/jama.2012.144878]
43. Gelu-Simeon M, Sobesky R, Haïm-Boukobza S, Ostos M, Teicher E, Fontaine H, et al. Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? *AIDS*. 2014; 28:1379-91 [PMID: 24785953; doi: 10.1097/QAD.0000000000000300]
44. Huang JF, Yu ML, Huang CF, Chiu CF, Dai CY, Huang CI, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapy - A multi center prospective trial. *Journal of Hepatology*. 2011; 54:216-26 [PMID: 21056500; doi: 10.1016/j.jhep.2010.07.011]
45. Pineda JA, Romero-Gómez M, Díaz-García F, Girón-González JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. *Hepatology*. 2005; 41:779 –89 [PMID: 15800956]
46. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. *AIDS*. 2004; 18:2285–93 [PMID: 15577541]
47. Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. *J Hepatol*. 2007; 47:527–37 [PMID: 17692986]
48. García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. *Am J Gastroenterol*. 2001; 96:179–83 [PMID: 11197250]
49. Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, et al. Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard. *Oncologist*. 2011; 16:1258-69 [PMID: 21868692; doi: 10.1634/theoncologist.2010-0400]
50. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*. 2006; 295:65-73 [PMID: 16391218]
51. Andrisani OM, Barnabas S. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). *Int J Oncol*. 1999; 15:373-9 [PMID: 10402250]

52. Rodríguez-Méndez ML, González-Quintela A, Aguilera A, Barrio E. Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. *Am J Gastroenterol*. 2000; 95:1316-22. [PMID: 10811346 ]
53. Thompson MA, Aberg JA, Hoy JF, Jen CL, You SL, Lu SN, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA*. 2012; 308:387–402 [PMID: 22820792; doi: 10.1001/jama.2012.7961]
54. Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. *Liver Cancer*. 2012; 1:226–37 [PMID: 24159587; doi: 10.1159/000343837]
55. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet*. 2003; 362:1907-17 [PMID: 14667750]
56. Herman P, Perini MV, Coelho FF, Kruger JA, Lupinacci RM, Fonseca GM, et al. Laparoscopic resection of hepatocellular carcinoma: when, why, and how? A single-center experience. *J Laparoendosc Adv Surg Tech A*. 2014; 24:223-8. [PMID: 24568364; doi: 10.1089/lap.2013.0502]
57. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med*. 1996; 334:693-9 [PMID: 8594428]
58. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. *Liver Transpl*. 2002; 8:765-74 [PMID: 12200775]
59. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol*. 2001; 35:421-30 [PMID: 11592607]
60. Livraghi T. Radiofrequency Ablation of Hepatocellular Carcinoma. *Surgical Oncology Clinics of North America*. 2011; 20:281-99 [PMID: 21377584]
61. Künzli BM, Abitabile P, Maurer CA. Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future. *World J Hepatol*. 2011; 3:8-14. [PMID: 21307982; doi: 10.4254/wjh.v3.i1.8]
62. Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. *Liver Transpl*. 2004; 10:S98–106 [PMID: 14762848]
63. Rhim H, Lim HK, Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma. *World J Gastrointest Surg*. 2010; 2:128-36. [PMID: 21160861; doi: 10.4240/wjgs.v2.i4.128]
64. Rhim H, Lim HK, Kim YS, Choi D, Lee WJ. Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures. *J Gastroenterol Hepatol*. 2008; 23:1492–500 [PMID: 18713294]
65. Xu RH, Gao W, Wang C, Guo DK, Tang L, Zhang H, et al. Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis. *Eur J Med Res*. 2014; 19:39. [PMID: 25141776; doi: 10.1186/2047-783X-19-39]
66. Powles T, Nelson M, Bower M. HIV-related lung cancer – a growing concern? *Int J STD AIDS*. 2003; 14:647-51 [PMID: 14596765]
67. Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, et al. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepaviv and CO12 Cirvir). *Clin Res Hepatol Gastroenterol*. 2012; 36:214–21 [PMID: 22189509; doi: 10.1016/j.clinre.2011.11.002]

68. Lim C, Goutte N, Gervais A, Vullierme M-P, Valla DC, Degos F, et al. Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma. *J Acquir Immune Defic Syndr*. 2012; 61:581–7 [PMID: 22918160; doi: 10.1097/QAI.0b013e31826ebdc7]
69. Merchante N, Merino E, Lopez-Aldeguer J, Jover F, Delgado-Fernandez M, Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. *Clin Infect Dis*. 2013; 56:143–50 [PMID: 22955438; doi: 10.1093/cid/cis777]
70. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. *J Infect Dis*. 2003; 188:1412–20 [PMID: 14624365]
71. Baccarani U, Righi E, Adani GL, Lorenzin D, Pasqualucci A, Bassetti M, et al. Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. *World J Gastroenterol*. 2014; 20:5353–62 [PMID: 24833865; doi: 10.3748/wjg.v20.i18.5353]
72. Vibert E, Duclos-Vallée J-C, Ghigna M-R, Hoti E, Salloum C, Guettier C, et al. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. *Hepatology*. 2011; 53:475–82 [PMID: 21274869; doi: 10.1002/hep.24062]
73. Samuel D, Weber R, Stock P, Duclos-Vallée J-C, Terrault N. Are HIV-infected patients candidates for liver transplantation? *J Hepatol*. 2008; 48:697–707 [PMID: 18331763; doi: 10.1016/j.jhep.2008.02.009]
74. Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. *Liver Transpl*. 2004; 10:S39–S53 [PMID: 15382219]
75. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. *Transplantation*. 2003; 76:370–5 [PMID: 12883195]
76. Duclos-Vallee JC, Vittecoq D, Teicher E, Feray C, Roque-Afonso AM, Lombes A, et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. *J Hepatol*. 2005; 42:341–9 [PMID: 15710216]
77. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. *Liver Transpl*. 2003; 9:239–47 [PMID: 12619020]
78. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. *Liver Transpl*. 2012; 18:716–26 [PMID: 22328294; doi: 10.1002/lt.23411]
79. Di Benedetto N, Peralta M, Alvarez E, Schroder MT, Estepo C, Paz S, et al. Incidence of hepatocellular carcinoma in hepatitis C cirrhotic patients with and without HIV infection: a cohort study, 1999–2011. *Ann Hepatol*. 2013 Jan–2014 Feb; 13:38–44 [PMID: 24378264]
80. Pache I, Duclos-Valle JC, Teicher E, Bismuth H, Castaing D, Vittecoq D, et al. Indications and timing for liver transplantation in HIV-coinfected patients. *Hepatology*. 2004; 40:356A
81. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including  $\alpha$ -fetoprotein improves the performance of Milan criteria. *Gastroenterology*. 2012; 143:986–94e3 [PMID: 22750200; doi: 10.1053/j.gastro.2012.05.052]
82. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. *Semin Liver Dis*. 2006; 26:273–84 [PMID: 16850377]

83. Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. *J Clin Oncol*. 2003; 21:1922-7 [PMID: 12743144]
84. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008; 359:378–90 [PMID: 18650514; doi: 10.1056/NEJMoa0708857]
85. De Nardo P, Viscione M, Corpolongo A, Bellagamba R, Vennarecci G, Ettorre GM, et al. Treatment of recurrent hepatocellular carcinoma with sorafenib in a HIV/HCV coinfecting patient in HAART: a case report. *Infect Agents Cancer*. 2012; 7:15 [PMID: 22741810; doi: 10.1186/1750-9378-7-15]
86. Perboni G, Costa P, Fibbia GC, Morandini B, Scalzini A, Tagliani A, et al. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfecting patient: a case report. *Oncologist*. 2010; 15:142–5 [PMID: 20142333 ; doi: 10.1634/theoncologist.2010-0010]
87. Ozenne V, Gervais A, Peytavin G, Castelnau C, Valla DC, Degos F. Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. *Hepatogastroenterology*. 2011; 58:161–2 [PMID: 21510306]
88. Mancuso A, Zavaglia C, Bai F, Puoti M, Belli LS. Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients. *Aliment Pharmacol Ther*. 2013; 38:1414-6 [PMID: 24206381; doi: 10.1111/apt.12536]
89. Berretta M, Di Benedetto F, Dal Maso L, Cacopardo B, Nasti G, Facchini G, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. *Anticancer Drugs*. 2013; 24:212–8 [PMID: 23197082; doi: 10.1097/CAD.0b013e32835c032f]
90. Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. *New Microbiol*. 2012; 35:113-59 [PMID: 22707127]
91. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Last accessed at: <http://aidsinfo.nih.gov/guidelines> on March 16th 2015.
92. Soriano V, de Mendoza C, Fernández-Montero JV, Labarga P, Barreiro P. Management and treatment of chronic hepatitis B in HIV-positive patients. *Ann Med*. 2014; 46:290-6 [PMID: 24716736; doi: 10.3109/07853890.2014.899103]
93. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med*. 2004; 351:438-50 [PMID: 15282351]
94. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. *AIDS*. 2007; 21:1073-89 [PMID: 17502718]
95. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. *Lancet Infect Dis*. 2013; 13:597–605 [PMID: 23768747; doi: 10.1016/S1473-3099(13)70149-X]
96. Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, et al. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. *Can J Infect Dis Med Microbiol*. 2013; 24:217–38 [PMID: 24489565]
97. Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, et al. British HIV Association guidelines for



- the management of hepatitis viruses in adults infected with HIV 2013. *HIV Med.* 2013; 14 Suppl 4:1-71 [PMID: 24581304; doi: 10.1111/hiv.12106]
- 98.** Carosi G, Bruno R, Cariti G, Nasta P, Gulminetti R, Galli M, et al. OPERA: use of pegylated interferon plus ribavirin for treating hepatitis C/HIV co-infection in interferon-naïve patients. *Antivir Ther* 2014 Feb 28. [Epub ahead of print] [PMID: 24583976; doi: 10.3851/IMP2757]
- 99.** Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. *HIV Med.* 2014; 15:108–15 [PMID: 24025147; doi: 10.1111/hiv.12086]
- 100.** Sulkowski MS. Interferon-containing and interferon-free HCV therapy for HIV-infected patients. *Semin Liver Dis.* 2014; 34:72-8 [PMID: 24782260; doi: 10.1055/s-0034-1371012]
- 101.** Bichoupan K, Dieterich DT. Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals. *Drugs.* 2014; 74:951–61 [PMID: 24866024; doi: 10.1007/s40265-014-0232-6]
- 102.** Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. *Viral Hepatitis Therapy Study Group. J Hepatol.* 1999; 30:653–9 [PMID: 10207807]
- 103.** Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. *J Gastroenterol Hepatol.* 2005; 20:1553-9 [PMID: 16174073]
- 104.** Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. *Clin Gastroenterol Hepatol.* 2005; 3 Suppl 2:S141-3 [PMID: 16234063]
- 105.** Shiratori Y, Ito Y, Yokosuka O, Nakata R, Tanaka N, Arakawa Y, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. *Ann Intern Med.* 2005; 142:105–14 [PMID: 15657158]
- 106.** Yu ML, Lin SM, Chuang WL, Dai CY, Wuang JH, Lu SN, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. *Antivir Ther.* 2006; 11:985–94 [PMID: 17302368]
- 107.** Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alfa and ribavirin. *World J Gastroenterol.* 2007; 13:5648–53 [PMID: 17948941]
- 108.** Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, de Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. *Hepatology.* 2010; 52:833–44 [PMID: 20564351; doi: 10.1002/hep.23744]
- 109.** Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. *Clin Gastroenterol Hepatol.* 2010; 8:192–9 [PMID: 19879972; doi: 10.1016/j.cgh.2009.10.026]
- 110.** Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus–related liver cancer. *Hepatology.* 2000; 32:228-32 [PMID: 10915728]

- 591 111. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effect of long-term post-  
592 operative interferon- therapy on intrahepatic recurrence after resection of hepatitis C virus hepatocellular  
593 carcinoma. *Ann Intern Med.* 2001; 134:963-7 [PMID: 11352697]
- 594 112. Shiratori Y, Shiina S, Teratani T, Tanaka H, Shuto T, Yamazaki O, et al. Interferon therapy after tumor  
595 ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. *Ann*  
596 *Intern Med.* 2003; 138:299-306 [PMID: 12585827]
- 597 113. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al. Prospective randomized controlled study of  
598 interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary  
599 tumors. *Cancer.* 2004; 100:376-82 [PMID: 14716774]
- 600 114. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of log-term  
601 outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.  
602 *Br J Surg.* 2002; 89:418-22 [PMID: 11952580]
- 603 115. International Interferon-Hepatocellular Study Group. Effect of interferon- on progression of cirrhosis to  
604 hepatocellular carcinoma: a retrospective cohort study. *Lancet.* 1998; 351:1535-9 [PMID: 10326535]
- 605 116. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular  
606 carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. *Hepatology.* 2006; 44:1543-54  
607 [PMID: 17133492]
- 608 117. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment  
609 reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology.* 2013; 58:98–  
610 107 [PMID: 23213040; doi: 10.1002/hep.26180]
- 611 118. Wright TL. Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. *Hepatol*  
612 *Res.* 2007; 37 Suppl 2:S294-8 [PMID: 17877498]
- 613 119. Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for  
614 hepatocellular carcinoma in chronic hepatitis C patients. *World J Gastroenterol.* 2008; 14:6140-4 [PMID:  
615 18985803]
- 616 120. Bruno S, Stroffolini T, Colombo M, Bolani S, Benvegnù L, Mazzella G, et al. Sustained virological  
617 response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.  
618 *Hepatology.* 2007; 45:579–87 [PMID: 17326216]
- 619 121. Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic  
620 hepatitis C. *J Antimicrob Chemother.* 2004; 53:19-22 [PMID: 14657083 ]
- 621 122. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. *Gastroenterology.* 2004;  
622 127 Suppl 1:S294-302. [PMID: 15508097]
- 623 123. Practice guidelines for the treatment of hepatitis C: Recommendations from an AISFG/SIMIT/SIMAST  
624 Expert Opinion Meeting. *Dig Liver Dis.* 2010; 42:81-91 [PMID: 19748329; doi: 10.1016/j.dld.2009.08.001]
- 625 124. Lemoine M, Ingiliz P. Liver injury in HIV monoinfected patients: should we turn a blind eye to it? *Clin Res*  
626 *Hepatol Gastroenterol.* 2012; 36:441-7 [PMID: 23079114; doi: 10.1016/j.clinre.2012.06.002]
- 627 125. Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. Do HIV care providers appropriately  
628 manage hepatitis B in coinfecting patients treated with antiretroviral therapy? *Clin Infect Dis.* 2007; 44:996-1000  
629 [PMID: 17342656]